8 results on '"Puksa S"'
Search Results
2. MA 20.11 Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population
- Author
-
Goffin, J., primary, Pond, G., additional, Tremblay, A., additional, Johnston, M., additional, Goss, G., additional, Nicholas, G., additional, Martel, S., additional, Bhatia, R., additional, Liu, G., additional, Roberts, H., additional, Tammemägi, M., additional, Atkar-Khattra, S., additional, Tsao, M., additional, Lam, S., additional, and Puksa, S., additional
- Published
- 2017
- Full Text
- View/download PDF
3. OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study
- Author
-
Tammemägi, M., primary, Schmidt, H., additional, Martel, S., additional, Mcwilliams, A., additional, Goffin, J., additional, Johnston, M., additional, Goss, G., additional, Tremblay, A., additional, Bhatia, R., additional, Liu, G., additional, Soghrati, K., additional, Yasufuku, K., additional, Hwang, D., additional, Laberge, F., additional, Gingras, M., additional, Pasian, S., additional, Couture, C., additional, Mayo, J.R., additional, Fauerbach, P.V. Nasute, additional, Atkar-Khattra, S., additional, Peacock, S.J., additional, Cressman, S., additional, Ionescu, D., additional, English, J.C., additional, Finley, R.J., additional, Yee, J., additional, Puksa, S., additional, Stewart, L., additional, Tsai, S., additional, Haider, E., additional, Boylan, C., additional, Cutz, J., additional, Manos, D., additional, Xu, Z., additional, Nicholas, G., additional, Seely, J.M., additional, Amjadi, K., additional, Sekhon, H.S., additional, Burrowes, P., additional, Maceachern, P., additional, Urbanski, S., additional, Sin, D., additional, Tan, W.C., additional, Leighl, N., additional, Shepherd, F., additional, Evans, W., additional, Tsao, M., additional, and Lam, S., additional
- Published
- 2017
- Full Text
- View/download PDF
4. Usefulness of transbronchial biopsy in immunosuppressed patients with pulmonary infiltrates.
- Author
-
Puksa, S, Hutcheon, M A, and Hyland, R H
- Abstract
In a retrospective study of thirty-one immunosuppressed patients with new pulmonary infiltrates transbronchial biopsy provided a specific diagnosis in 11 of the 31 (36%) patients. In a further five patients, whose biopsy showed non-specific interstitial pneumonitis, a specific diagnosis was established by other means. Overall a specific diagnosis was obtained in 52% of patients. Twelve patients were left with a diagnosis of non-specific interstitial pneumonitis. In three out of 31 (10%) patients insufficient tissue was obtained. The seven patients who had metastatic carcinoma of the lung did poorly. The nine with other specific diagnoses did better in that five of them were alive after more than 11 months of follow-up. Patients with non-specific pneumonitis did well; eight out of 12 (67%) were alive after an average follow-up of 13.4 months. In 27 of the 31 (87%) patients the procedure was felt to have influenced therapeutic decisions. This was true whether the biopsy yielded a specific or a non-specific diagnosis. In our series making a specific diagnosis did not improve the patients' survival. Those with non-specific pneumonitis who were treated empirically did well, as did patients with specific diagnoses other than metastatic carcinoma of the lung. [ABSTRACT FROM AUTHOR]
- Published
- 1983
5. Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population.
- Author
-
Goffin JR, Pond GR, Puksa S, Tremblay A, Johnston M, Goss G, Nicholas G, Martel S, Bhatia R, Liu G, Schmidt H, Atkar-Khattra S, McWilliams A, Tsao MS, Tammemagi MC, and Lam S
- Subjects
- Aged, Canada epidemiology, Early Detection of Cancer, Emphysema diagnostic imaging, Female, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Pulmonary Disease, Chronic Obstructive epidemiology, Pulmonary Emphysema complications, Risk Factors, Spirometry, Tomography, X-Ray Computed, Lung Neoplasms diagnostic imaging, Mass Screening methods, Pulmonary Disease, Chronic Obstructive diagnosis, Smoking adverse effects
- Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an underdiagnosed condition sharing risk factors with lung cancer. Lung cancer screening may provide an opportunity to improve COPD diagnosis. Using Pan-Canadian Early Detection of Lung Cancer (PanCan) study data, the present study sought to determine the following: 1) What is the prevalence of COPD in a lung cancer screening population? 2) Can a model based on clinical and screening low-dose CT scan data predict the likelihood of COPD?, Methods: The single arm PanCan study recruited current or former smokers age 50-75 who had a calculated risk of lung cancer of at least 2% over 6 years. A baseline health questionnaire, spirometry, and low-dose CT scan were performed. CT scans were assessed by a radiologist for extent and distribution of emphysema. With spirometry as the gold standard, logistic regression was used to assess factors associated with COPD., Results: Among 2514 recruited subjects, 1136 (45.2%) met spirometry criteria for COPD, including 833 of 1987 (41.9%) of those with no prior diagnosis, 53.8% of whom had moderate or worse disease. In a multivariate model, age, current smoking status, number of pack-years, presence of dyspnea, wheeze, participation in a high-risk occupation, and emphysema extent on LDCT were all statistically associated with COPD, while the overall model had poor discrimination (c-statistic = 0.627 (95% CI of 0.607 to 0.650). The lowest and the highest risk decile in the model predicted COPD risk of 27.4 and 65.3%., Conclusions: COPD had a high prevalence in a lung cancer screening population. While a risk model had poor discrimination, all deciles of risk had a high prevalence of COPD, and spirometry could be considered as an additional test in lung cancer screening programs., Trial Registration: (Clinical Trial Registration: ClinicalTrials.gov, number NCT00751660 , registered September 12, 2008).
- Published
- 2020
- Full Text
- View/download PDF
6. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.
- Author
-
Cressman S, Peacock SJ, Tammemägi MC, Evans WK, Leighl NB, Goffin JR, Tremblay A, Liu G, Manos D, MacEachern P, Bhatia R, Puksa S, Nicholas G, McWilliams A, Mayo JR, Yee J, English JC, Pataky R, McPherson E, Atkar-Khattra S, Johnston MR, Schmidt H, Shepherd FA, Soghrati K, Amjadi K, Burrowes P, Couture C, Sekhon HS, Yasufuku K, Goss G, Ionescu DN, Hwang DM, Martel S, Sin DD, Tan WC, Urbanski S, Xu Z, Tsao MS, and Lam S
- Subjects
- Aged, Cost-Benefit Analysis, Female, Humans, Incidence, Lung Neoplasms pathology, Male, Middle Aged, Retrospective Studies, Early Detection of Cancer economics, Lung Neoplasms economics, Mass Screening economics
- Abstract
Introduction: Lung cancer risk prediction models have the potential to make programs more affordable; however, the economic evidence is limited., Methods: Participants in the National Lung Cancer Screening Trial (NLST) were retrospectively identified with the risk prediction tool developed from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. The high-risk subgroup was assessed for lung cancer incidence and demographic characteristics compared with those in the low-risk subgroup and the Pan-Canadian Early Detection of Lung Cancer Study (PanCan), which is an observational study that was high-risk-selected in Canada. A comparison of high-risk screening versus standard care was made with a decision-analytic model using data from the NLST with Canadian cost data from screening and treatment in the PanCan study. Probabilistic and deterministic sensitivity analyses were undertaken to assess uncertainty and identify drivers of program efficiency., Results: Use of the risk prediction tool developed from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial with a threshold set at 2% over 6 years would have reduced the number of individuals who needed to be screened in the NLST by 81%. High-risk screening participants in the NLST had more adverse demographic characteristics than their counterparts in the PanCan study. High-risk screening would cost $20,724 (in 2015 Canadian dollars) per quality-adjusted life-year gained and would be considered cost-effective at a willingness-to-pay threshold of $100,000 in Canadian dollars per quality-adjusted life-year gained with a probability of 0.62. Cost-effectiveness was driven primarily by non-lung cancer outcomes. Higher noncurative drug costs or current costs for immunotherapy and targeted therapies in the United States would render lung cancer screening a cost-saving intervention., Conclusions: Non-lung cancer outcomes drive screening efficiency in diverse, tobacco-exposed populations. Use of risk selection can reduce the budget impact, and screening may even offer cost savings if noncurative treatment costs continue to rise., (Crown Copyright © 2017. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
7. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.
- Author
-
Cressman S, Lam S, Tammemagi MC, Evans WK, Leighl NB, Regier DA, Bolbocean C, Shepherd FA, Tsao MS, Manos D, Liu G, Atkar-Khattra S, Cromwell I, Johnston MR, Mayo JR, McWilliams A, Couture C, English JC, Goffin J, Hwang DM, Puksa S, Roberts H, Tremblay A, MacEachern P, Burrowes P, Bhatia R, Finley RJ, Goss GD, Nicholas G, Seely JM, Sekhon HS, Yee J, Amjadi K, Cutz JC, Ionescu DN, Yasufuku K, Martel S, Soghrati K, Sin DD, Tan WC, Urbanski S, Xu Z, and Peacock SJ
- Subjects
- Canada, Cost-Benefit Analysis, Early Detection of Cancer economics, Early Detection of Cancer methods, Female, Humans, Lung Neoplasms diagnosis, Male, Mass Screening economics, Middle Aged, Randomized Controlled Trials as Topic economics, Randomized Controlled Trials as Topic methods, Tomography, X-Ray Computed economics, Lung Neoplasms diagnostic imaging, Mass Screening methods, Tomography, X-Ray Computed methods
- Abstract
Background: It is estimated that millions of North Americans would qualify for lung cancer screening and that billions of dollars of national health expenditures would be required to support population-based computed tomography lung cancer screening programs. The decision to implement such programs should be informed by data on resource utilization and costs., Methods: Resource utilization data were collected prospectively from 2059 participants in the Pan-Canadian Early Detection of Lung Cancer Study using low-dose computed tomography (LDCT). Participants who had 2% or greater lung cancer risk over 3 years using a risk prediction tool were recruited from seven major cities across Canada. A cost analysis was conducted from the Canadian public payer's perspective for resources that were used for the screening and treatment of lung cancer in the initial years of the study., Results: The average per-person cost for screening individuals with LDCT was $453 (95% confidence interval [CI], $400-$505) for the initial 18-months of screening following a baseline scan. The screening costs were highly dependent on the detected lung nodule size, presence of cancer, screening intervention, and the screening center. The mean per-person cost of treating lung cancer with curative surgery was $33,344 (95% CI, $31,553-$34,935) over 2 years. This was lower than the cost of treating advanced-stage lung cancer with chemotherapy, radiotherapy, or supportive care alone, ($47,792; 95% CI, $43,254-$52,200; p = 0.061)., Conclusion: In the Pan-Canadian study, the average cost to screen individuals with a high risk for developing lung cancer using LDCT and the average initial cost of curative intent treatment were lower than the average per-person cost of treating advanced stage lung cancer which infrequently results in a cure.
- Published
- 2014
- Full Text
- View/download PDF
8. Powassan encephalitis: a case report with neuropathology and literature review.
- Author
-
Gholam BI, Puksa S, and Provias JP
- Subjects
- Encephalitis, Tick-Borne pathology, Humans, Male, Middle Aged, Brain pathology, Encephalitis, Tick-Borne diagnosis
- Published
- 1999
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.